series-c-plus
Stage
3
Investors
About
Faraday Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics to address ischemia-reperfusion injury and other critical care illnesses, with its lead product FDY-5301 undergoing Phase 3 trials for reducing cardiovascular mortality and heart failure in acute ST-elevation myocardial infarction patients.
Explore Faraday Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.